Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lytic Cycle of Bacteriophages

Lytic Cycle of Bacteriophages

Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the...

Lysogenic Cycle of Bacteriophages

Lysogenic Cycle of Bacteriophages

In contrast to the lytic cycle, phages infecting bacteria via the lysogenic cycle do not immediately kill their host cell. Instead, they combine their genome with the host genome, allowing the bacteria to replicate the phage DNA along with the bacterial genome. The incorporated copy of the phage genome is called the prophage. Some prophages can re-activate and enter the lytic cycle. This often occurs in response to a perturbation, such as DNA damage, but can also transpire in the absence of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Single Treatment of Mature 3D Single-, Dual- and Poly-Species Biofilms Using a Combination Therapy of Phage or Phage-Hetero-Cocktails and Ciprofloxacin.

Antibiotics (Basel, Switzerland)·2026

Same author

Towards a reference methodology for bacteriophage susceptibility testing - position paper of the EUCAST Phage Susceptibility Testing Subcommittee.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026

Same author

DepoCatalog: mapping diversity of 129 recombinantly produced Klebsiella phage depolymerases.

Nature communications·2026

Same author

Assetizing Diversity: Microbial Culture Collections in an Age of Biotechnology, Biodiversity, and Speculative Value Generation (1972-2022).

Journal of the history of biology·2026

Same author

Culture, Codes, Communities: Culture Collections' Transformation from Microbial Palaces to Networked Services (1890-1972).

Journal of the history of biology·2026

Same author

Pyrogenicity of phage active pharmaceutical ingredients used for personalized therapy in Belgium.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026

Search research articles

Related Experiment Video

Updated: May 21, 2025

Understanding the Impact of Temperate Bacteriophages on Their Lysogens Through Transcriptomics

Understanding the Impact of Temperate Bacteriophages on Their Lysogens Through Transcriptomics

Published on: January 5, 2024

Addressing the Research and Development Gaps in Modern Phage Therapy.

Paul E Turner^1,2,3, Joana Azeredo^4,5, Ed T Buurman⁶

¹Department of Ecology and Evolutionary Biology, Yale University, New Haven, Connecticut, USA.

PHAGE (New Rochelle, N.Y.)

|March 21, 2025

Summary

This summary is machine-generated.

Phage therapy is a promising approach to combat rising antimicrobial resistance. This review explores challenges and innovations in phage R&D, aiming for accessible treatments for bacterial infections.

Keywords:

antimicrobial resistance biofilm biotechnology patient access personalized medicine

More Related Videos

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings

Published on: August 19, 2021

Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice

Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice

Published on: January 26, 2024

Related Experiment Videos

Last Updated: May 21, 2025

Understanding the Impact of Temperate Bacteriophages on Their Lysogens Through Transcriptomics

Understanding the Impact of Temperate Bacteriophages on Their Lysogens Through Transcriptomics

Published on: January 5, 2024

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings

Published on: August 19, 2021

Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice

Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice

Published on: January 26, 2024

Area of Science:

Microbiology
Biotechnology
Infectious Diseases

Background:

Global rise in antimicrobial resistance necessitates novel therapeutic strategies.
Bacteriophage (phage) therapy presents a viable alternative to conventional antibiotics for treating bacterial infections.
Significant challenges hinder the widespread R&D and clinical application of phage therapy.

Purpose of the Study:

To review the current landscape of phage therapy research and development.
To identify and discuss key operational, epistemic, and biological challenges in phage R&D.
To explore emerging technologies and approaches, including AI and synthetic biology, for advancing phage therapy.

Main Methods:

Comprehensive literature review of phage therapy research.
Analysis of R&D challenges and opportunities in the context of antimicrobial drug discovery.
Discussion of commercialization and accessibility models for phage-based therapeutics.

Main Results:

Phage R&D faces hurdles in standardization, regulatory pathways, and understanding phage-bacteria interactions.
Artificial intelligence and synthetic biology offer potential solutions for phage discovery, engineering, and production.
Current antimicrobial innovation models present limitations for phage therapy development and market entry.

Conclusions:

Overcoming R&D challenges is crucial for realizing the full potential of phage therapy.
Innovative approaches are needed to ensure equitable global access to phage-based treatments.
Exploring alternative funding and production models is essential for sustainable phage therapy development.